Literature DB >> 18692805

Comparative effects of atorvastatin and simvastatin on the plasma total homocysteine levels in women with polycystic ovary syndrome: a prospective randomized study.

Cemil Kaya1, Sevim Dinçer Cengiz, Bülent Berker, Selda Demirtaş, Mustafa Cesur, Gürbüz Erdoğan.   

Abstract

OBJECTIVE: To test the hypothesis that statins improve hyperhomocysteinemia in women with polycystic ovary syndrome (PCOS).
DESIGN: A prospective randomized study.
SETTING: University Hospital. PATIENT(S): Fifty-two women with PCOS and 52 women matched for age and body mass index as controls. INTERVENTION(S): Patients were randomly divided into two groups for treatment: group 1, atorvastatin, 20 mg daily (n = 26), and group 2, simvastatin, 20 mg daily (n = 26). Blood samples were obtained before and after treatment. MAIN OUTCOME MEASURE(S): Serum homocysteine levels. RESULT(S): After 12 weeks of treatment, serum homocysteine levels in group 1 had decreased from 14.3 +/- 2.9 to 10.6 +/- 1.7 micromol/L; in group 2, the levels decreased from 13.6 +/- 2.1 to 11.1 +/- 1.9 micromol/L. Both two groups, free testosterone and total testosterone declined statistically significantly (38.3% and 36.5%; and 40.6% and 46.0%, respectively). In group 1, vitamin B(12) increased from 362.1 +/- 107 to 478.7 +/- 267 pg/mL; in group 2, it increased from 391.3 +/- 107 to 466 +/- 211 pg/mL, but the change did not reach statistical significance. There was a considerable decline in the homeostatic model assessment index in group 1 (40.0% to 32.1%). CONCLUSION(S): Treatment with statins in women with PCOS leads to decreases in serum homocysteine levels.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18692805     DOI: 10.1016/j.fertnstert.2008.06.006

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  15 in total

Review 1.  Emerging concepts about prenatal genesis, aberrant metabolism and treatment paradigms in polycystic ovary syndrome.

Authors:  Selma F Witchel; Sergio E Recabarren; Frank González; Evanthia Diamanti-Kandarakis; Kai I Cheang; Antoni J Duleba; Richard S Legro; Roy Homburg; Renato Pasquali; Rogerio A Lobo; Christos C Zouboulis; Fahrettin Kelestimur; Franca Fruzzetti; Walter Futterweit; Robert J Norman; David H Abbott
Journal:  Endocrine       Date:  2012-06-04       Impact factor: 3.633

2.  Inadequacy of initiating rosuvastatin then metformin on biochemical profile of polycystic ovarian syndrome patients.

Authors:  G Ghazeeri; H A Abbas; B Skaff; S Harajly; J Awwad
Journal:  J Endocrinol Invest       Date:  2015-02-27       Impact factor: 4.256

3.  Comparison of effects of different statins on growth and steroidogenesis of rat ovarian theca-interstitial cells.

Authors:  Anna Sokalska; Scott D Stanley; Jesus A Villanueva; Israel Ortega; Antoni J Duleba
Journal:  Biol Reprod       Date:  2014-02-27       Impact factor: 4.285

Review 4.  Medical management of metabolic dysfunction in PCOS.

Authors:  Antoni J Duleba
Journal:  Steroids       Date:  2011-12-13       Impact factor: 2.668

5.  Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial.

Authors:  Nazia Raja-Khan; Allen R Kunselman; Cynthia S Hogeman; Christy M Stetter; Laurence M Demers; Richard S Legro
Journal:  Fertil Steril       Date:  2010-12-08       Impact factor: 7.329

6.  Statins inhibit growth of human theca-interstitial cells in PCOS and non-PCOS tissues independently of cholesterol availability.

Authors:  Anna Sokalska; Piotr C Piotrowski; Izabela J Rzepczynska; Amanda Cress; Antoni J Duleba
Journal:  J Clin Endocrinol Metab       Date:  2010-09-08       Impact factor: 5.958

7.  Effect of lipopenic and hypotensive treatment on homocysteine levels in type 2 diabetics.

Authors:  Mabrouka El Oudi; Zied Aouni; Haroun Ouertani; Chakib Mazigh; Salem Machghoul
Journal:  Vasc Health Risk Manag       Date:  2010-05-25

8.  Variants in the HMG-CoA reductase (HMGCR) gene influence component phenotypes in polycystic ovary syndrome.

Authors:  Ning Xu; Kent D Taylor; Ricardo Azziz; Mark O Goodarzi
Journal:  Fertil Steril       Date:  2009-03-26       Impact factor: 7.329

Review 9.  Extra- and intra-ovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence.

Authors:  Jie Qiao; Huai L Feng
Journal:  Hum Reprod Update       Date:  2010-07-16       Impact factor: 15.610

10.  Cardiovascular Risk in Women With PCOS.

Authors:  Pietro Scicchitano; Ilaria Dentamaro; Rosa Carbonara; Gabriella Bulzis; Annamaria Dachille; Paola Caputo; Roberta Riccardi; Manuela Locorotondo; Cosimo Mandurino; Marco Matteo Ciccone
Journal:  Int J Endocrinol Metab       Date:  2012-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.